Joel Jiang

8.4k total citations · 2 hit papers
24 papers, 3.6k citations indexed

About

Joel Jiang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joel Jiang has authored 24 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joel Jiang's work include Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (5 papers). Joel Jiang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (5 papers). Joel Jiang collaborates with scholars based in United States, United Kingdom and Spain. Joel Jiang's co-authors include Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Dirk Schadendorf, Jeffrey S. Weber, Ian M. Waxman, Christopher D. Lao, Caroline Robert, Hewei Li and Georgina V. Long and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Joel Jiang

22 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology profile →
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

2017 874 citations Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Jiang United States	16	2.4k	964	930	670	650	24	3.6k
Oliver Klein Australia	25	1.6k 0.7×	658 0.7×	513 0.6×	582 0.9×	348 0.5×	64	2.7k
John H. Yim United States	30	1.0k 0.4×	684 0.7×	585 0.6×	510 0.8×	272 0.4×	79	2.6k
Rebecca A. Moss United States	24	4.0k 1.7×	945 1.0×	959 1.0×	212 0.3×	954 1.5×	74	5.5k
Yukio Hosomi Japan	28	2.5k 1.0×	878 0.9×	285 0.3×	170 0.3×	2.1k 3.2×	189	3.7k
Yoshito Akagi Japan	32	1.8k 0.8×	786 0.8×	363 0.4×	158 0.2×	741 1.1×	272	3.3k
Kerry L. Reynolds United States	36	3.7k 1.5×	581 0.6×	727 0.8×	71 0.1×	1.2k 1.8×	153	5.0k
William N. William United States	33	2.0k 0.8×	893 0.9×	371 0.4×	173 0.3×	1.5k 2.3×	109	4.0k
Stéphane Éderhy France	27	1.3k 0.5×	449 0.5×	239 0.3×	100 0.1×	525 0.8×	116	3.0k
David Nathanson United States	24	901 0.4×	608 0.6×	203 0.2×	509 0.8×	213 0.3×	76	2.1k
Atsuhiko Sakamoto Japan	28	1.0k 0.4×	618 0.6×	207 0.2×	1.1k 1.6×	397 0.6×	126	3.5k

Countries citing papers authored by Joel Jiang

Since Specialization

Citations

This map shows the geographic impact of Joel Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Jiang more than expected).

Fields of papers citing papers by Joel Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Jiang. The network helps show where Joel Jiang may publish in the future.

Co-authorship network of co-authors of Joel Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Jiang. A scholar is included among the top collaborators of Joel Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Jiang. Joel Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bissonnette, Robert, Jennifer Soung, Adelaide A. Hebert, et al.. (2025). POS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial. Annals of the Rheumatic Diseases. 84. 1167–1168.

Summers, Jessica J., et al.. (2022). Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis. PLoS ONE. 17(3). e0265879–e0265879. 15 indexed citations

McDonald, Craig M., Francesco Muntoni, Mark Rance, et al.. (2021). Ataluren Delays Loss of Ambulation and Decline in Pulmonary Function in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (2553). Neurology. 96(15_supplement). 1 indexed citations

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology. 19(11). 1480–1492. 1009 indexed citations breakdown →

Kollmeier, Alexa P., Andrew Greenspan, X. L. Xu, et al.. (2018). Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H₄R‐antagonist (JNJ‐39758979) in adults with uncontrolled asthma. Clinical & Experimental Allergy. 48(8). 957–969. 10 indexed citations

Popat, Sanjay, Andrea Ardizzoni, T-E. Ciuleanu, et al.. (2017). Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Annals of Oncology. 28. v463–v463. 29 indexed citations

Barros, Milton, Andréia Cristina de Melo, Sérgio Jobim Azevedo, et al.. (2017). Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment. Cancer Research. 77(13_Supplement). LB–55.

Hogg, David, Paul B. Chapman, Mario Sznol, et al.. (2017). Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology. 35(15_suppl). 9522–9522. 6 indexed citations

Weber, Jeffrey S., F. Stephen Hodi, Jedd D. Wolchok, et al.. (2017). Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology. 35(7). 785–792. 874 indexed citations breakdown →

10.

Tawbi, Hussein, Peter Forsyth, Alain P. Algazi, et al.. (2017). Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. Journal of Clinical Oncology. 35(15_suppl). 9507–9507. 97 indexed citations

11.

Weber, Jeffrey S., Ryan J. Sullivan, Jeffrey A. Sosman, et al.. (2016). Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. The Lancet Oncology. 17(7). 943–955. 257 indexed citations

12.

George, Saby, Robert J. Motzer, Hans J. Hammers, et al.. (2016). Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. JAMA Oncology. 2(9). 1179–1179. 142 indexed citations

13.

Wolchok, Jedd D., Vanna Chiarion‐Sileni, René González, et al.. (2016). Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology. 34(15_suppl). 9505–9505. 63 indexed citations

14.

Larkin, James, Jean‐Jacques Grob, C. Lance Cowey, et al.. (2015). Efficacy and Safety in Key Patient Subgroups of Nivolumab (Nivo) Alone Or Combined with Ipilimumab (Ipi) Versus Ipi Alone in Treatment-Naive Patients with Advanced Melanoma. 2 indexed citations

15.

Larkin, James, Christopher D. Lao, Walter J. Urba, et al.. (2015). Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma. JAMA Oncology. 1(4). 433–433. 171 indexed citations

16.

Larkin, James, Vanna Chiarion‐Sileni, R. Gonzalez, et al.. (2015). 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European Journal of Cancer. 51. S664–S665. 27 indexed citations

17.

Barchuk, William, John M. Lambert, Rainard Fuhr, et al.. (2014). Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma. Pulmonary Pharmacology & Therapeutics. 29(1). 15–23. 18 indexed citations

18.

Yale, J.‐F., G. Bakris, Bertrand Cariou, et al.. (2014). Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obesity and Metabolism. 16(10). 1016–1027. 224 indexed citations

19.

Neal, Bruce, Vlado Perkovic, Dick de Zeeuw, et al.. (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. American Heart Journal. 166(2). 217–223.e11. 278 indexed citations

20.

Lucasti, Christopher, Abel Jasovich, Obiamiwe Umeh, et al.. (2008). Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clinical Therapeutics. 30(5). 868–883. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact